Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LGMN | Q99538 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25194853 | 0.86 | LMNA (0.65) | MAPTRAB9AMAPK1KDM4EHSD17B10 | |
| SCHEMBL31038214 | 0.86 | LMNA (0.65) | MAPTRAB9AMAPK1KDM4EHSD17B10 | |
| SCHEMBL2948496 | 0.83 | MAPK1 (0.41) | MAPTRAB9AMAPK1KDM4ETSHR | |
| SCHEMBL16648517 | 0.82 | GPR119 (0.52) | MAPTRAB9AMAPK1KDM4ETSHR | |
| SCHEMBL12639922 | 0.81 | LMNA (0.46) | KDM4EKMT2ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL31038223 | 0.80 | LMNA (0.58) | MAPTKDM4EHSD17B10HPGDLMNA | |
| SCHEMBL25197786 | 0.80 | LMNA (0.58) | MAPTKDM4EHSD17B10HPGDLMNA | |
| SCHEMBL6870510 | 0.79 | LGMN (0.59) | MAPTRAB9AMAPK1KDM4ETSHR | |
| SCHEMBL12288882 | 0.79 | CYP3A4 (0.51) | MAPTRAB9AKDM4EKMT2APOLB | |
| SCHEMBL6180885 | 0.79 | MAPT (0.53) | MAPTRAB9AMAPK1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854678-B | RIPK1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116854678-A | RIPK1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-2922821-B1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2922821-B1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC (US) | 2019-07-31 | — | — | EP | disclosed |
| US-9771326-B2 | S1P and/or ATX modulating agents | BIOGEN MA INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771326-B2 | S1P and/or ATX modulating agents | BIOGEN MA INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771326-B2 | S1P and/or ATX modulating agents | BIOGEN MA INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20150299123-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2015-10-22 | — | — | US | disclosed |
| US-20150299123-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2015-10-22 | — | — | US | disclosed |
| US-20150299123-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2015-10-22 | — | — | US | disclosed |
| WO-2014081756-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| EP-0844877-B1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ASTRAZENECA AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| EP-0925286-B1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2003-01-02 | — | — | EP | disclosed |
| US-6093718-A | AN OXIDO-SQUALENE CYCLASE INHIBITOR, ANTICHOLESTEROL AGENT FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND LOWERING CHOLESTEROL LEVELS IN BLOOD PLASMA; TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2000-07-25 | — | — | US | disclosed |
| US-6090813-A | Use of oxido-squalene cyclase inhibitors to lower blood cholesterol | ZENECA LIMITED (GB) | 2000-07-18 | — | — | US | disclosed |
| CN-1228087-A | Substituted pyrimidine derivatives and their pharmaceutical use | ZENECA LTD (GB) | 1999-09-08 | — | — | CN | disclosed |
| EP-0925286-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| EP-0844877-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1998006705-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1998-02-19 | — | — | WO | disclosed |
| WO-1997006802-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299123-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | MAPT 3910/4885RAB9A 1680/4885MAPK1 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.